The global market for endoscopic retrograde cholangiopancreatography (ERCP) devices is set to experience significant growth over the next decade, with estimates predicting sales to increase from USD 1 ...
To keep it up and running, organs located in the systems throughout the body work diligently to keep up with life’s daily ...
Viking Therapeutics, Inc. ("Viking") , a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that the company ...
A recent study revealed that the neutrophil-to-high-density lipoprotein cholesterol ratio (NHR) could be a useful tool to identify individuals at risk of developing gallstone disease (GSD).
Tharimmune, Inc. ("Tharimmune" or the "Company"), a clinical-stage biotechnology company developing a portfolio of therapeutic candidates in inflammation and immunology, received positive feedback ...
For primary biliary cirrhosis, ursodeoxycholic acid ... is important. For metabolic disorders such as nonalcoholic fatty liver diseases, amelioration of the metabolic condition is important ...
CHOLBAM is FDA-approved for the treatment of bile acid synthesis disorders due to single enzyme ... and Phase 2b VANTAGE study for primary biliary cholangitis. Volixibat has been granted ...
Dr. Falk Pharma is excited about the addition of KNS366 to its R&D pipeline and will further explore the potential of KNS366 ...
The DWP has confirmed that 7.0 million people in England, Scotland, and Wales were receiving financial support through Universal Credit by the end of September ...
AX-0810 targeting NTCP for cholestatic diseases to be first ProQR Axiomer™ RNA editing program to enter the clinic Company to host virtual ...
Department of Paediatrics at Government Medical College (GMC) Srinagar hosted a national-level conference on paediatric ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback